Tirzepatide deep-dive Tirzepatide is made by Eli Lilly under two brand names: Mounjaro -- weekly injection, FDA-approved for type 2 diabetes in 2022 (doses 2.5 mg through 15 mg) Zepbound -- weekly injection, FDA-approved for chronic weight management in November 2023 [4] The headline trial is SURMOUNT-1: 2,539 adults without diabetes, BMI of 30 or higher (or 27 with a weight-related condition), randomized across three tirzepatide doses (5, 10, 15 mg) versus placebo for 72 weeks
Assessment and history A structured history should aim to distinguish (a) true vaginal mucosal symptoms, (b) vulvar dermatologic disease, (c) urinary tract symptoms, and (d) sexual function/arousal issues
Intentional use of carbapenem antibiotics for valproic acid toxicity: A case report
10.1089/ars.2021.0073 [DOI] [PMC free article] [PubMed] [Google Scholar] Konopka A
Mounjaro (tirzepatide) Information What is Mounjaro